The first at-home taVNS device built on the JAMA 2024 dosing protocol.
Lull is a non-invasive, FDA-listed Class II transcutaneous auricular vagus nerve stimulator. The 20-minute nightly dosing protocol was published in JAMA Internal Medicine, 2024, and Lull was engineered around it from the ground up.
- FDA-listed Class II medical device, manufactured in the US
- Built on the published JAMA 2024 protocol — 20 minutes nightly, clipped to the cymba conchae
- Developed alongside clinical sleep researchers and autonomic-nervous-system specialists
- Backed by a 60-night home trial — try it for two cycles, send it back if it doesn't work
"Honestly, I read the actual JAMA paper before buying. Once I saw the dosing protocol was real published science, I trusted it more than anything else I'd tried."


